The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Boehringer Ingelheim focuses on targeting the proteins involved in this process as a promising strategy for developing new cancer treatments. Credit: Tada Images/Shutterstock. Boehringer Ingelheim and ...

Under development at German family-owned pharma major Boehringer Ingelheim, survodutide is a dual glucagon/GLP-1 receptor agonist for the treatment of adults living with non-cirrhotic metabolic ...

IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) today announced the results of the special meeting of its stockholders held on September ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ...

The Angelika Amon research building is named after a Viennese pioneer in cell biology who was closely connected with Boehringer Ingelheim. Image credit: Boehringer Ingelheim. Boehringer Ingelheim has ...